INSTITUTE OF CELLULAR THERAPIES
DENVAXTM
DENDRITIC CELL THERAPY
Customized Cell-based Cancer Immunotherapy
INSTITUTE OF CELLULAR THERAPIES PVT.LTD.
J-3
Sector 41
Noida, UP 201303
India
ph: 91-120-2500111
fax: 91-120-4317902
alt: 91-120-2500195
info
To manufacture a single dose of DENVAX the following steps are taken:
STEP 1
To manufacture a single dose of Dendritic cell cancer vaccine (DENVAXTM), a fresh sample of peripheral blood (20-40 ml in amount as per the TLC count) of the patient is collected in CellNuteTM medium provided by ICT Lab Services.
The day blood is drawn is considered 'Day 1' of the protocol.
STEP 2
Peripheral blood mononuclear (CD14+) cells are isolated and cultured in cytokines along with the desired nutritional media.
STep 3
These cells transform into 'immature' dendritic cells. For maturation, these cells are exposed to cancerous antigen on Day 6 of blood drawl.
Exposure of DC to cancerous antigen leads to maturation of dendritic cells, ready for infusion into the patient, on day 8.
step 4
The mature dendritic cells harvested on day 8 are re-infused into the same patient, intravenously as infusion.Cancerous antigenS
Cancerous antigens are bits of protein required for maturation of dendritic cells. This cancerous antigen may be extracted from either source:
a) The patient's wax embedded tissue: tumor tissue preserved in wax for biopsy examination for further studies;
b) Formalin fixed tissue: patient's tumor tissue preserved in formalin at the time of surgery for further studies;
c) Fresh FNA tissue: fresh sample of tumor tissue derived from Fine Needle Aspiration
Copyright Institute of Cellular Therapies Pvt. Ltd.
All rights reserved.
Last updated on 19 October, 2011
INSTITUTE OF CELLULAR THERAPIES PVT.LTD.
J-3
Sector 41
Noida, UP 201303
India
ph: 91-120-2500111
fax: 91-120-4317902
alt: 91-120-2500195
info
